Show simple item record

dc.contributor.authorXia, Jun
dc.contributor.authorAdams, Clive E.
dc.date.accessioned2017-10-30T11:08:23Z
dc.date.available2017-10-30T11:08:23Z
dc.date.issued2009
dc.identifier.citationXia, J., Adams, C. E., Bhagat, N., Bhagat, V., Bhoopathi, P., El-Sayeh, H., Pinfold, V. & Takriti, Y. (2009). Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin, 33 (7), pp.254-257.en
dc.identifier.other10.1192/pb.bp.108.021949
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9776
dc.description.abstractAIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.en
dc.description.urihttps://www.cambridge.org/core/journals/psychiatric-bulletin/article/losing-participants-before-the-trial-ends-erodes-credibility-of-findings/8ECF898917C72AFF772E758874C198B7
dc.subjectSchizophreniaen
dc.subjectClinical trialen
dc.titleLosing participants before the trial ends erodes credibility of findingsen
dc.typeArticle


This item appears in the following Collection(s)

Show simple item record